Micrornas: New players in multiple myeloma

Frontiers in Genetics

Volumn 2, Issue MAY, 2011, Pages

  Pichiorri, Flavia ^a,b   De Luca, Luciana ^c   Aqeilan, Rami I ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

MDM2; Microarray; MiRNAs; Multiple myeloma; P53; Profiling

Indexed keywords

EID: 84865537671     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2011.00022     Document Type: Article

References (70)

1. A.C.S. (2010). Multiple Myeloma. Available at http://www.cancer.org/ Cancer/MultipleMyeloma/index
2. Ambros, V. (2003). MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113, 673-676.
3. Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350-355.
4. Anderson, K. C. (2011). Oncogen omics to target myeloma in the bone marrow microenvironment. Clin. Cancer Res. 17, 1225-1233.
5. Aqeilan, R. I., Calin, G. A., and Croce, C. M. (2010). miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 17, 215-220.
6. Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monconduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A. M., Sotto, J. J., Wetterwald, M., Dumontet, C., Fuzibet, J. G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J. L., Facon, T., and Mathiot, C. (2007). Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109, 3489-3495.
7. Bartel, D. P. (2004). MicroRNAs: genom-ics, biogenesis, mechanism, and function. Cell 116, 281-297.
8. Bommert, K., Bargou, R. C., and Stuhmer, T. (2006). Signalling and survival pathways in multiple myeloma. Eur. J Cancer 42,1574-1580.
9. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., and Lane, D. P. (2009). Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862-873.
10. Calin, G. A., and Croce, C. M. (2006). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66, 7390-7394.
11. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., and Croce, C. M. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 15524-15529.
12. Calin, G. A., Liu, C. G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., Dell'aquila, M. L., Alder, H., Rassenti, L., Kipps, T. J., Bullrich, F., Negrini, M., and Croce, C. M. (2004). MicroRNA profiling reveals distinct signatures in B cell chronic lympho-cytic leukemias. Proc. Natl. Acad. Sci. U.S.A. 101, 11755-11760.
13. Chen, Y. H., Lavelle, D., Desimone, J., Uddin, S., Platanias, L. C., and Hankewych, M. (1999). Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleu-kin-6 receptors but through upregulation of p21(WAF1). Blood 94, 251-259.
14. Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., Fonseca, R., Kremer, R., Cattoretti, G., and Bergsagel, P. L. (2008). AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167-180.
15. Chim, C. S., Wong, K. Y., Qi, Y., Loong, F., Lam, W. L., Wong, L. G., Jin, D. Y., Costello, J. F., and Liang, R. (2010). Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31, 745-750.
16. Chng, W. J., Glebov, O., Bergsagel, P. L., and Kuehl, W. M. (2007). Genetic events in the pathogenesis of multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 571-596.
17. Corthals, S. L., Jongen-Lavrencic, M., De Knegt, Y., Peeters, J. K., Beverloo, H. B., Lokhorst, H. M., and Sonneveld, P. (2010). Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk. Res. 34, 677-681.
18. Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., De Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., Helin, K., Pelicci, P. G., Jochemsen, A. G., and Marine, J. C. (2004). Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 24, 5835-5843.
19. Dickens, M. P., Fitzgerald, R., and Fischer, P. M. (2010). Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin. Cancer Biol. 20, 10-18.
20. Diederichs, S., and Haber, D. A. (2007). Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 131, 1097-1108.
21. Fabbri, M., Croce, C. M., and Calin, G. A. (2009). MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk. Lymphoma 50, 160-170.
22. Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, E E., Drach, J., Greipp, P. R., Kirsch, I. R., Kuehl, W. M., Hernandez, J. M., Minvielle, S., Pilarski, L. M., Shaughnessy, J. D. Jr., Stewart, A. K., and Avet-Loiseau, H. (2004). Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 64, 1546-1558.
23. Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., Neri, A., Barlogie, B., Kuehl, W. M., Liebisch, P., Davies, F., Chen-Kiang, S., Durie, B. G., Carrasco, R., Sezer, O., Reiman, T., Pilarski, L., and Avet-Loiseau, H. (2009). International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210-2221.
24. Gatt, M. E., Zhao, J. J., Ebert, M. S., Zhang, Y., Chu, Z., Mani, M., Gazit, R., Carrasco, D. E., Dutta-Simmons, J., Adamia, S., Minvielle, S., Tai, Y. T., Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., and Carrasco, D. R. (2010). MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood (in press).
25. Gutierrez, N. C., Sarasquete, M. E., Misiewicz-Krzeminska, I., Delgado, M., De Las Rivas, J., Ticona, E V., Ferminan, E., Martin-Jimenez, P., Chillon, C., Risueno, A., Hernandez, J. M., Garcia-Sanz, R., Gonzalez, M., and San Miguel, J. E. (2010). Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 24,629-637.
26. He, L., and Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531.
27. He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., and Hammond, S. M. (2005). A micro-RNA polycistron as a potential human oncogene. Nature 435, 828-833.
28. Jiang, J., Lee, E. J., Gusev, Y., and Schmittgen, T. D. (2005). Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33, 5394-5403.
29. Junttila, M. R., and Evan, G. I. (2009). p53 - a Jack of all trades but master of none. Nat. Rev. Cancer 9, 821-829.
30. Kastrinakis, N. G., Gorgoulis, V. G., Foukas, P. G., Dimopoulos, M. A., and Kittas, C. (2000). Molecular aspects of multiple myeloma. Ann. Oncol. 11, 1217-1228.
31. Katz, B. Z. (2010). Adhesion molecules -The lifelines of multiple myeloma cells. Semin. Cancer Biol. 20, 186-195.
32. Kuehl, W. M., and Bergsagel, P. L. (2002). Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175-187.
33. Kumar, M., Lu, Z., Takwi, A. A., Chen, W., Callander, N. S., Ramos, K. S., Young, K. H., and Li, Y. (2010). Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 30, 843-853.
34. Lane, D. (2001). How cells choose to die. Nature 414, 25, 27.
35. Lavelle, D., Chen, Y. H., Hankewych, M., and Desimone, J. (2001). Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am. J. Hematol. 68, 170-178.
36. Linares, L. K., Kiernan, R., Triboulet, R., Chable-Bessia, C., Latreille, D., Cuvier, O., Lacroix, M., Le Cam, L., Coux, O., and Benkirane, M. (2007). Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 9, 331-338.
37. Lionetti, M., Agnelli, L., Mosca, L., Fabris, S., Andronache, A., Todoerti, K., Ronchetti, D., Deliliers, G. L., and Neri, A. (2009). Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 48, 521-531.
38. Liu, C. G., Spizzo, R., Calin, G. A., and Croce, C. M. (2008). Expression profiling of microRNA using oligo DNA arrays. Methods 44, 22-30.
39. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L., and Hannon, G. J. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441.
40. Lode, L., Eveillard, M., Trichet, V., Soussi, T., Wuilleme, S., Richebourg, S., Magrangeas, F., Ifrah, N., Campion, L., Traulle, C., Guilhot, F., Caillot, D., Marit, G., Mathiot, C., Facon, T., Attal, M., Harousseau, J. L., Moreau, P., Minvielle, S., and Avet-Loiseau, H. (2010). Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95, 1973-1976.
41. Loffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermuller, J., Kretzschmar, A. K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K., Cvijic, H., Ullmann, A. K., Stadler, P. F., and Horn, E (2007). Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330-1333.
42. Mahindra, A., Hideshima, T., and Anderson, K. C. (2010). Multiple myeloma: biology of the disease. Blood Rev. 24(Suppl. 1), S5-S11.
43. Neben, K., Jauch, A., Bertsch, U., Heiss, C., Hielscher, T., Seckinger, A., Mors, T., Müller, N. Z., Hillengass, J., Raab, M. S., Ho, A. D., Hose, D., and Goldschmidt, H. (2010). Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95, 1150-1157.
44. O'carroll, D., Mecklenbrauker, I., Das, P. P., Santana, A., Koenig, U., Enright, A. J., Miska, E. A., and Tarakhovsky, A. (2007). A slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev. 21, 1999-2004.
45. Ota, A., Tagawa, H., Karnan, S., Tsuzuki, S., Karpas, A., Kira, S., Yoshida, Y., and Seto, M. (2004). Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lym-phoma. Cancer Res. 64, 3087-3095.
46. Pichiorri, F., Suh, S. S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P., Munker, R., Volinia, S., Boccadoro, M., Garzon, R., Palumbo, A., Aqeilan, R. I., and Croce, C. M. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogen-esis. Proc. Natl. Acad. Sci. U.S.A. 105, 12885-12890.
47. Pichiorri, F., Suh, S. S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M. Jr., Hofmainster, C., Alder, H., Garofalo, M., Di Leva, G., Volinia, S., Lin, H. J., Perrotti, D., Kuehl, M., Aqeilan, R. I., Palumbo, A., and Croce, C. M. (2010). Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367-381.
48. Quesnel, B., Preudhomme, C., Oscier, D., Lepelley, P., Collyn-D'hooghe, M., Facon, T., Zandecki, M., and Fenaux, P. (1994). Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br. J. Haematol. 88, 415-418.
49. Roccaro, A. M., Sacco, A., Thompson, B., Leleu, X., Azab, A. K., Azab, F., Runnels, J., Jia, X., Ngo, H. T., Melhem, M. R., Lin, C. P., Ribatti, D., Rollins, B. J., Witzig, T. E., Anderson, K. C., and Ghobrial, I. M. (2009). MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113, 6669-6680.
50. Ronchetti, D., Lionetti, M., Mosca, L., Agnelli, L., Andronache, A., Fabris, S., Deliliers, G. L., and Neri, A. (2008). An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med. Genomics 1, 37. doi: 10.1186/1755-8794-1-37
51. Saha, M. N., Jiang, H., Jayakar, J., Reece, D., Branch, D. R., and Chang, H. (2010a). MDM2 antagonist nutlin plus protea-some inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol. Ther. 9, 936-944.
52. Saha, M. N., Micallef, J., Qiu, L., and Chang, H. (2010b). Pharmacological activation of the p53 pathway in haematological malignancies. J. Clin. Pathol. 63, 204-209.
53. Sarasquete, M. E., Gutierrez, N. C., Misiewicz-Krzeminska, I., Paiva, B., Chillon, M. C., Alcoceba, M., Garcia-Sanz, R., Hernandez-Rivas, J. M., Gonzalez, M., and San Miguel, J. F. (2010). Up-regulation of dicer is more frequent in monoclonal gammopa-thies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 96, 468-471.
54. Sawyer, J. R. (2011). The prognostic significance of cytogenetics and molecular profiling in multile myleoma. Cancer Genet. 204, 3-12.
55. Schiltz, R. L., and Nakatani, Y. (2000). The PCAF acetylase complex as a potential tumor suppressor. Biochim. Biophys. Acta 1470, M37-M53.
56. Schmittgen, T. D., Jiang, J., Liu, Q., and Yang, L. (2004). A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res. 32, e43.
57. Shaughnessy, J. D. Jr., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S. G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., Van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J., and Barlogie, B. (2007). A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276-2284.
58. Stuhmer, T., and Bargou, R. C. (2006). Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies. Cell Cycle 5, 39-42.
59. Teoh, G., Urashima, M., Ogata, A., Chauhan, D., Decaprio, J. A., Treon, S. P., Schlossman, R. L., and Anderson, K. C. (1997). MDM2 protein overex-pression promotes proliferation and survival of multiple myeloma cells. Blood 90, 1982-1992.
60. Unno, K., Zhou, Y., Zimmerman, T., Platanias, L. C., and Wickrema, A. (2009). Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk. Lymphoma 50, 1865-1871.
61. Vaissiere, T., Sawan, C., and Herceg, Z. (2008). Epigenetic interplay between histone modifications and DNAmeth-ylation in gene silencing. Mutat. Res. 659, 40-48.
62. Ventura, A., and Jacks, T. (2009). MicroRNAs and cancer: short RNAs go a long way. Cell 136, 586-591.
63. Ventura, A., Kirsch, D. G., Mclaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., and Jacks, T. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665.
64. Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., Jaenisch, R., Sharp, P. A., and Jacks, T. (2008). Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875-886.
65. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce, C. M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261.
66. Walker, B. A., Wardell, C. P., Chiecchio, L., Smith, E. M., Boyd, K. D., Neri, A., Davies, F. E., Ross, F. M., and Morgan, G. J. (2011). Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117, 553-562.
67. Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., and Kuehl, W. M. (2009). A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418-5422.
68. Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., and Rajewsky, K. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9, 405-414.
69. Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S. W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
70. Zhou, Y., Chen, L., Barlogie, B., Stephens, O., Wu, X., Williams, D. R., Cartron, M. A., Van Rhee, F., Nair, B., Waheed, S., Pineda-Roman, M., Alsayed, Y., Anaissie, E., and Shaughnessy, J. D. Jr. (2010). High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/ AGO2. Proc. Natl. Acad. Sci. U.S.A. 107, 7904-7909.